Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman C, Thompson A, Tintoré M, Uitdehaag B. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler. 2009 Jun;15(6):715-20.

 

Camiña-Tato M, Morcillo-Suárez C, Navarro A, Fernández M, Horga A, Montalban X, Comabella M. Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. J Neuroimmunol. 2009 Aug 18; 213(1-2): 142-7.

 

Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009 Aug; 66 (8): 972-8.

 

Comabella M, Domínguez C, Rio J, Martín-Gallán P, Vilches A, Vilarrasa N, Espejo C, Montalban X. Plasma chitotriosidase activity in multiple sclerosis. Clin Immunol. 2009 May;131(2):216-22.

 

Comabella M, Fernández-Arquero M, Río J, Guinea A, Fernández M, Cenit MC, de la Concha EG, Montalban X. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2009 May 29;210(1-2):116-9.

 

Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. A type I interferon signature in monocytes is associated with poor response to interferon-{beta} in multiple sclerosis. Brain. 2009 Dec;132(Pt 12):3353-65.

 

Comabella M, Pradillo JM, Fernández M, Río J, Lizasoain I, Julià E, Moro MA, Sastre-Garriga J, Montalban X. Plasma levels of 15d-PGJ are not altered in multiple sclerosis MS. Eur J Neurol. 2009 Nov; 16(11):1197-201.

 

Comabella M, Río J, Espejo C, Ruiz de Villa M, Al-Zayat H, Nos C, Deisenhammer F, Baranzini SE, Nonell L, López C, Julià E, Oksenberg JR, Montalban X. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol. 2009 Feb;130 (2): 145-50.

 

Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung H, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr K, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; for the PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 31; 374(9700): 1503-11.

 

Cotte S, Kruse N, Zettl UK, Téllez N, Lühder F, Koepsell H, Montalban X, Gold R, von Ahsen and Chan A. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009 Sep; 132(Pt 9): 2517-30.

 

De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study, Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW, Freedman MS, Edan G, Hartung HP, Polman CH, Kappos L, Montalbán X, Miller D, O'Connor P, Hartung HP, Comi G, Filippi M, Kappos L, Arnason BG, Cook S, Goodin DS, Jeffery D, Traboulsee A, Ebers GC, Langdon D, Goodin DS, Reder AT, Zipp F, Schimrigk S, Hartung HP, Filippi M, Hillert J. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009 Dec; 8(12): 1111-9.

 

Eixarch H, Gómez A, Kádár E, George M, Martínez N, Espejo C, Petriz J, Barquinero J. Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice. Mol Ther. 2009 Nov; 17(11):1904-9.

 

Eixarch H, Espejo C, Gómez A, Mansilla MJ, Castillo M, Mildner A, Vidal F, Gimeno R, Prinz M, Montalban X, Barquinero J. Tolerance induction in experimental autoimmune encephalomyelitis using gene therapy with autoantigen. Mol Ther. 2009 May;17(5):897-905.

 

Julià E, Edo MC, Horga A, Montalban X, Comabella M. Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. Clin Immunol. 2009 Dec;133(3):364-74.

 

Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; for the BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009 Nov; 8(11): 987-97.

 

Korteweg T, Tintore M, Uitdehaag BM, Knol DL, Vrenken H, Rovira A, Frederiksen J, Miller DH, Fernando K, Filippi M, Agosta F, Rocca MA, Fazekas F, Enzinger C, Parry A, Polman CH, Montalban X, Barkhof F. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. Eur Radiol. 2009 Sep; 19(9):2244-8.

 

Llufriu S, Castillo J, Blanco Y, Ramió-Torrentà L, Río J, Vallès M, Lozano M, Castellá MD, Calabia J, Horga A, Graus F, Montalban X, Saiz A. Plasma Exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology. 2009 Sep 22;73(12):949-53.

 

Mancini L, Ciccarelli O, Manfredonia F, Thornton JS, Agosta F, Barkhof F, Beckmann C, De Stefano N, Enzinger C, Fazekas F, Filippi M, Gass A, Hirsch JG, Johansen-Berg H, Kappos L, Korteweg T, Manson SC, Marino S, Matthews PM, Montalban X, Palace J, Polman C, Rocca M, Ropele S, Rovira A, Wegner C, Friston K, Thompson A, Yousry T. Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis. Neuroimage 2009 Apr 1;45(2):500-11.

 

Montalban X, Sastre-Garriga J, Filippi M, Khaleeli Z, Téllez N, Vellinga MM, Tur C, Brochet B, Barkhof F, Rovaris M, Miller DH, Polman CH, Rovira A, Thompson AJ. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. Mult Scler. 2009 Dec;15(12):1459-65.

 

Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich X, Río J, Porcel J, Borrás C, Nos C, Rovira A. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009 Oct; 15(10): 1195-205.

 

Montalban X. Multiple Sclerosis therapy: historical and future perspectives. Curr Opin in Neurology. 2009 : 22(1); S1-S3.

 

Moraal B, Pohl C, Uitdehaag BM, Polman CH, Edan G, Freedman MS, Hartung HP, Kappos L, Miller DH, Montalban X, Lanius V, Sandbrink R, Barkhof F. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol. 2009 Nov; 66(11): 1345-52.

 

O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L; FTY720 D2201 Study Group. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology. 2009 Jan 6;72(1):73-9.

 

Pareés I, Alonso J, Rovira A, Martínez E, Montalban X. Síndrome opticomedular como forma de presentación de un astrocitoma difuso. Rev Neurol. 2009 Apr 1-15;48(7):354-6.

 

Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B. Revision of the risk of secondary leukemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler. 2009 Dec; 15(11): 1303-11.

 

Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, Nos C, Comabella M, Aymerich X, Montalbán X. Measures in the first year of the therapy predict the response to interferon beta in MS. Mult. Scler. 2009 Jul; 15(7): 848-53.

 

Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009 Oct; 5 (10): 553-60.

 

Río-Izquierdo J, Montalban X. Natalizumab en esclerosis múltiple. Rev Neurol 2009 Sep 1-15; 49 (5): 265-9

 

Rocca MA, Absinta M, Valsasina P, Ciccarelli O, Mariano S, Rovira A, Gass A, Wegner C, Enzinger C, Korteweg T, Sormani MP, Manchini L, Thompson AJ, De Stefano N, Montalban X, Hirsh J, Kappos L, Ropele S, Palace J, Barkhof F, Matthews PM, Filippi M. Abnormal connectivity of the sensorimotor network in patients with MS: A multicentre fMRI study. Hum Brain Mapp. 2009 Aug; 30(8): 2412-25.

 

Rovaris M, Barkhof F, Calabrese M, De Stefano N, Fazekas F, Miller DH, Montalban X, Polman C, Rocca MA, Thompson AJ, Yousry TA, Filippi M. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype. Neurology. 2009 May;72(19):1693-701.

 

Rovira A, Swanton J, Tintoré M, Huerga E, Barkhof F, Filippi M, Frederiksen JL, Langkilde A, Miszkiel K, Polman C, Rovaris M, Sastre-Garriga J, Miller D, Montalban X. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol. 2009 May;66(5):587-92.

 

Sánchez-Valle R, Nos C. Fenotipado molecular de la enfermedad de Creutzfeldt-Jakob. Alzheimer. Real Invest Demenc. 2009; (42): 2-3.

 

Sastre-Garriga J, Arévalo MJ, Renom M, Alonso J, González I, Galán I, Montalban X, Rovira A. Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis. J Neurol Sci. 2009; 282(1-2):120-124.

 

Sormani MP, Filippi M, De Stefano N, MAGNIMS Steering Committee, Ebers G, Daumer M. MRI as an outcome in multiple sclerosis clinical trials. Neurology. 2009 Dec 1; 73(22): 1932-3.

 

Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van, Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009 Dec 1;73(22):1914-22.

 

Tintoré M, Arrambide G. Early onset multiple sclerosis: The role of gender. J Neurol Sci. 2009 Nov 15;286(1-2):31-4.

 

Tintore M, Sastre-Garriga J. Role of MRI criteria and OB for diagnosing multiple sclerosis in patients presenting with clinically isolated syndromes. Mult Scler. 2009 Apr;15(4):407-8.

 

Tintoré M. New options for early treatment of multiple sclerosis. J Neurol Sci. 2009 Feb 1;277 Suppl 1:S9-S11.

 

Tumani H, Hartung HP, Hemmer B, Teunissen C, Deisenhammer F, Giovannoni G, Zettl UK, Altintas A, Bennett JL, Berven FS, Brundin L, Comabella M, Federiksen JL, Fleming JO, Franciotta D, Furlan R, Hintzen RQ, Johnson MH, Krasulova E, Kuhle J, Petzold A, Rajda C,Rejdak K, van Pesch V, Waubant E; BioMS Study Group. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 2009 Aug;35(2):117-27.

 

Vamdembroeck K, Comabella M, Tolosa E, Goertsches R, Brassat D, Hintzen R, Infante-Duarte C, Favorov A, Escorza S, Palacios R, Oksenberg JR, Villoslada P. United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics. 2009 May; 10(5): 885-894.